MA46523A - Procédés de criblage de modulateurs d'une activité biologique de type gdf15 - Google Patents
Procédés de criblage de modulateurs d'une activité biologique de type gdf15Info
- Publication number
- MA46523A MA46523A MA046523A MA46523A MA46523A MA 46523 A MA46523 A MA 46523A MA 046523 A MA046523 A MA 046523A MA 46523 A MA46523 A MA 46523A MA 46523 A MA46523 A MA 46523A
- Authority
- MA
- Morocco
- Prior art keywords
- gdf15
- processes
- biological activity
- type biological
- screening modulators
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662407046P | 2016-10-12 | 2016-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46523A true MA46523A (fr) | 2019-08-21 |
Family
ID=60186389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046523A MA46523A (fr) | 2016-10-12 | 2017-10-11 | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20190234935A1 (fr) |
EP (1) | EP3526346A1 (fr) |
JP (1) | JP2020503842A (fr) |
KR (1) | KR20190059312A (fr) |
AU (1) | AU2017342028A1 (fr) |
CA (1) | CA3038846A1 (fr) |
IL (1) | IL265808A (fr) |
MA (1) | MA46523A (fr) |
WO (1) | WO2018071493A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102370762B1 (ko) | 2016-03-31 | 2022-03-04 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 결합 단백질 및 이의 사용 방법 |
US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
KR20210044244A (ko) | 2018-08-10 | 2021-04-22 | 노파르티스 아게 | Gfral 세포외 도메인 및 사용 방법 |
IL291985A (en) | 2019-10-07 | 2022-06-01 | Kallyope Inc | gpr119 agonists |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
EP4172162A1 (fr) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Activateurs d'ampk |
WO2023154953A1 (fr) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
AU669489B2 (en) | 1991-09-18 | 1996-06-13 | Affymax Technologies N.V. | Method of synthesizing diverse collections of oligomers |
PT665897E (pt) | 1992-10-01 | 2003-11-28 | Trustees Of Columbia U In The | Bibliotecas quimicas combinatorias complexas codificadas com etiquetas |
AU703472B2 (en) | 1993-11-02 | 1999-03-25 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
EP0758313A4 (fr) | 1994-05-06 | 1999-09-15 | Pharmacopeia Inc | Bibliotheque combinatoire de dihydrobenzopyranes |
US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
US6010861A (en) | 1994-08-03 | 2000-01-04 | Dgi Biotechnologies, Llc | Target specific screens and their use for discovering small organic molecular pharmacophores |
PT2441466E (pt) * | 2004-04-13 | 2014-09-09 | St Vincents Hosp Sydney | Agente de inibição de mic-1 |
CA2832581C (fr) * | 2011-04-08 | 2022-08-23 | Yumei Xiong | Methode de traitement ou d'amelioration de troubles metaboliques a l'aide du facteur 15 de differenciation de croissance (gdf-15) |
BR112014018575A2 (pt) * | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
CN106536553B (zh) * | 2014-03-26 | 2021-03-12 | 尤利乌斯·马克西米利安维尔茨堡大学 | 生长和分化因子15(gdf-15)的单克隆抗体及其治疗癌性恶病质和癌症的用途 |
EP3157952B1 (fr) * | 2014-06-20 | 2021-12-22 | Aveo Pharmaceuticals, Inc. | Traitement de l'insuffisance cardiaque congestive et d'autres dysfonctionnements cardiaques à l'aide d'un modulateur gdf15 |
ES2872534T3 (es) * | 2014-09-25 | 2021-11-02 | Aveo Pharmaceuticals Inc | Métodos para revertir la caquexia y prolongar la supervivencia que comprenden administrar un modulador de GDF15 y un agente anticanceroso |
JP2019510739A (ja) * | 2016-02-29 | 2019-04-18 | イーライ リリー アンド カンパニー | Gfral受容体療法 |
KR102370762B1 (ko) * | 2016-03-31 | 2022-03-04 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 결합 단백질 및 이의 사용 방법 |
-
2017
- 2017-10-11 CA CA3038846A patent/CA3038846A1/fr not_active Abandoned
- 2017-10-11 EP EP17791242.5A patent/EP3526346A1/fr not_active Withdrawn
- 2017-10-11 US US16/341,074 patent/US20190234935A1/en not_active Abandoned
- 2017-10-11 WO PCT/US2017/056069 patent/WO2018071493A1/fr unknown
- 2017-10-11 JP JP2019519691A patent/JP2020503842A/ja active Pending
- 2017-10-11 KR KR1020197012471A patent/KR20190059312A/ko active Search and Examination
- 2017-10-11 MA MA046523A patent/MA46523A/fr unknown
- 2017-10-11 AU AU2017342028A patent/AU2017342028A1/en not_active Abandoned
-
2019
- 2019-04-03 IL IL265808A patent/IL265808A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL265808A (en) | 2019-06-30 |
US20190234935A1 (en) | 2019-08-01 |
CA3038846A1 (fr) | 2018-04-19 |
JP2020503842A (ja) | 2020-02-06 |
EP3526346A1 (fr) | 2019-08-21 |
WO2018071493A1 (fr) | 2018-04-19 |
KR20190059312A (ko) | 2019-05-30 |
AU2017342028A1 (en) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA46523A (fr) | Procédés de criblage de modulateurs d'une activité biologique de type gdf15 | |
MA56008A (fr) | Composés et compositions pour traiter des états associés à une activité de nlrp | |
MA46278A (fr) | Molécules de liaison qui modulent une activité biologique exprimée par une cellule | |
MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
MA44734A (fr) | Composés et compositions destinés au traitement d'états associés à une activité de nlrp | |
GB202001657D0 (en) | Prediction of adverse drug reactions | |
MA42269A (fr) | Compositions et procédés d'inhibition de l'activité de l'arginase | |
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
DK3134386T3 (da) | Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom | |
DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
MA43756A (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
BR112016030690A2 (pt) | moduladores do receptor de arila e métodos de fabricar e usar os mesmos | |
CL2015000717A1 (es) | Compuestos derivados de piridinonas biciclicas y sus sales; composicion farmaceutica que los comprende; y su uso para el tratamiento de la neurodegeneracion y trastornos psiquiatricos, que incluyen enfermedad de alzheimer o enfermedad de niemann-pick tipo c. | |
GB202015400D0 (en) | Adverse drug reaction analysis | |
MA49153A (fr) | Éléments régulateurs à haute activité | |
DK3463351T3 (da) | Behandling til parkinsons sygdom | |
GB201610425D0 (en) | Analysis of images of biological material | |
MA41198A (fr) | Essais d'activité enzymatique pour i2s | |
MA53014A (fr) | Composés améliorant l'activité du protéasome | |
FI20155241A (fi) | Menetelmä beta-spodumeenin valmistamiseksi alfa-spodumeenia sisältävästä raaka-aineesta | |
FR3039378B1 (fr) | Ensemble de conditionnement d'un produit cosmetique | |
MA50838A (fr) | Procédés de production de matieres végétales ensilées à l'aide de megasphaera elsdenii | |
IL291221A (en) | Methods for the synthesis of wolbenzine | |
FR3046471B1 (fr) | Methode de calibration d'une interface neuronale directe par regression multivoie penalisee | |
EP3623369C0 (fr) | Nouveaux composés de morpholinyle amine pour le traitement des maladies auto-immunes |